Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 6;7(3):107.
doi: 10.3390/vaccines7030107.

Original Antigenic Sin and Respiratory Syncytial Virus Vaccines

Ralph A Tripp  1 , Ultan F Power  2
Affiliations

Original Antigenic Sin and Respiratory Syncytial Virus Vaccines

Ralph A Tripp et al. Vaccines (Basel). .

Abstract

The original antigenic sin (OAS) theory considers the outcome of the first encounter with an antigen. It favors a memory response to the original antigen upon exposure to a similar or related antigen, and includes both positive and negative impacts of past exposure on the memory response to challenge, and, in particular, on vaccine efficacy. This phenomenon is closely linked with imprinting and the hierarchical nature of immune responses to previously encountered antigens. The focus of this commentary centers on the potential role of OAS or immunological imprinting on respiratory syncytial virus memory responses.

Keywords: OAS; RSV; VE; immunological memory; original antigenic sin; vaccine effectiveness; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Tripp R.A., Power U.F., Openshaw P.J.M., Kauvar L.M. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. J. Virol. 2018;92:e01302–e01317. doi: 10.1128/JVI.01302-17. - DOI - PMC - PubMed
    1. Jorquera P.A., Tripp R.A. Respiratory syncytial virus: Prospects for new and emerging therapeutics. Expert Rev. Respir. Med. 2017;11:609–615. doi: 10.1080/17476348.2017.1338567. - DOI - PubMed
    1. Jorquera P.A., Anderson L., Tripp R.A. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Rev. Vaccines. 2016;15:173–187. doi: 10.1586/14760584.2016.1115353. - DOI - PubMed
    1. Noor A., Krilov L.R. Respiratory syncytial virus vaccine: where are we now and what comes next? Expert Opin. Biol. Ther. 2018;18:1247–1256. doi: 10.1080/14712598.2018.1544239. - DOI - PubMed
    1. Mazur N.I., Higgins D., Nunes M.C., Melero J.A., Langedijk A.C., Horsley N., Buchholz U.J., Openshaw P.J., McLellan J.S., Englund J.A., et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect. Dis. 2018;18:e295–e311. doi: 10.1016/S1473-3099(18)30292-5. - DOI - PubMed

LinkOut - more resources